Your Notifications
All done, no notifications

CAR-T Cost in Mumbai

Costs starts from Get a Quote
Filters

Cost of CAR-T in Major Cities of India

CityMinimum Cost (USD)Minimum Cost (INR)Maximum Cost (USD)Maximum Cost (INR)
AmrohaUSD 640005480960USD 960008221440
DelhiUSD 800006851200USD 12000010276800
FaridabadUSD 800006851200USD 12000010276800
KochiUSD 800006851200USD 12000010276800
MumbaiUSD 800006851200USD 12000010276800

Need Help Planning Your Treatment Abroad?

Your 24/7 AI Health Assistant

CAR T-cell therapy represents a groundbreaking approach to harnessing the power of the body's immune system to combat cancer. By modifying T cells, a subset of white blood cells, in a laboratory setting, these cells are empowered to recognize and eliminate cancer cells with precision. Often categorized as a form of cell-based gene therapy, CAR T-cell therapy involves altering the genetic makeup of T cells, equipping them with the ability to target specific cancer antigens.

This innovative treatment has demonstrated remarkable efficacy, particularly in cases where conventional therapies have proven ineffective. Its ability to reprogram the immune system to target and destroy cancer cells marks a significant advancement in cancer treatment strategies.

Classification:

CAR T cell therapy is classified as follows:

  • Structure-based classification:
  • First-generation CAR T-cells: These CAR T-cells typically consist of an antigen-binding domain (single-chain variable fragment, scFv) linked to a T-cell activation domain, such as the CD3ζ chain. They lack additional co-stimulatory domains.
  • Second-generation CAR T-cells: These CAR T-cells include an additional co-stimulatory domain, such as CD28 or 4-1BB (CD137), along with the CD3ζ chain. The presence of co-stimulatory domains enhances T-cell activation and persistence.
  • Third-generation CAR T-cells: These CAR T-cells incorporate two co-stimulatory domains along with the CD3ζ chain, aiming to further enhance T-cell function and anti-tumor activity.

Antigen-based classification: It includes

  • CD19-targeted CAR T-cells: CD19 is a common target for CAR T-cell therapy and is used in the treatment of B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of lymphoma.
  • Other antigen-targeted CAR T-cells: CAR T-cells can be engineered to target a variety of antigens expressed on cancer cells, including but not limited to BCMA (B-cell maturation antigen), CD22, CD30, and EGFRvIII.

CAR T-cell therapy is primarily used to treat blood cancers, such as multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukaemia. The patient's own T cells are reprogrammed to identify and destroy cancer cells, cause remission, enhance survival, and have a plan B in case other treatments fail.

Patients with blood cancers who relapsed or are refractory must consult an oncologist to determine candidacy for CAR T therapy, especially if they have failed to respond to traditional treatments (i.e., chemotherapy, radiation, or stem cell transplant). Evaluation is warranted for symptoms such as loss of weight, swelling of lymph nodes, recurrent infection, chronic fatigue, or spontaneous bruising.

Screening tests consist of imaging, bone marrow biopsy, and blood work.Leukapheresis is utilised to harvest T cells from the patient's blood for T-cell collection.Bridging therapy: Certain patients receive chemotherapy while waiting for CAR T cells to be produced.Lymphodepleting chemotherapy is administered before the injection to make room for CAR T cells. The patients should plan for potential hospitalisation, designate caretakers, and discuss long-term follow-up and expected adverse effects with the medical team.

  • T-cell harvesting: T cells are removed from the patient's blood by processing.
  • Genetic alteration: T cells are designed in the laboratory to express CAR proteins targeting cancer cells.
  • Expansion: Modified T cells are expanded to therapeutic levels.
  • Infusion: Patient receives an intravenous infusion of CAR T cells.
  • Monitoring: Intensive monitoring, often in the hospital, for side effects and reactions.

The whole process, from cell harvesting to infusion, can take three to six weeks. The infusion itself takes a few hours to a few minutes, but for at least one week following the infusion, close monitoring is required, and there will be frequent follow-ups for several months.

  • Cytokine Release Syndrome (CRS)
  • Neurotoxicity
  • Infections
  • Low blood counts
  • Relapse or non-response

One of the newer treatment options for some blood cancers is CAR T-cell therapy. It is utilised when other treatments are not working or the cancer recurs. CAR T-cell therapy has the potential to cure many blood cancers and extend life in most cases.

Recovery involves managing side effects like CRS and neurotoxicity, monitoring blood levels, and avoiding infections. Laboratory testing, imaging, and monitoring for late issues like hypogammaglobulinemia or relapse are all included in long-term follow-up.

The nature of the cancer, the burden of the disease, and an individual's response all impact success. For example, in pediatric acute lymphoblastic leukaemia, complete remission rates are more than 80%. However, relapse is always a risk, and long-term success is variable.

Would you like some help? We are available.

Get Help
Explore Hospitals ( 3 )
CAR-T in Gleneagles Hospital Mumbai: Costs, Top Doctors, and Reviews

Mumbai, India

  • Joint Commission International, or JCI
  • Gleneagles Hospital, Parel, Mumbai, is a premier quaternary-care multispeciality hospital and a top destination for complex medical care in Western India.
  • Renowned for multi-organ transplants and advanced surgeries, the hospital offers specialised treatment across Cardiology, Neurology, Gastroenterology, Hepatology, Nephrology, Urology, Orthopaedics, Critical Care, Interventional Radiology, Gynaecology, and General Medicine.
  • Equipped with state-of-the-art diagnostic and surgical technology, including 3-Tesla MRI, 128-slice CT Scan, Bi-plane Cath Lab, and robotic surgery systems, Gleneagles provides integrated, patient-focused care.
  • Its expert team of doctors, nurses, and support staff ensures high standards of safety, efficiency, and compassionate care, making it a trusted healthcare destination for patients in Mumbai and beyond.
CAR-T in Fortis Hospital, Mulund: Costs, Top Doctors, and Reviews

Mumbai, India

  • Joint Commission International, or JCI
  • National Accreditation Board for Hospitals & Healthcare Providers (NABH)

Fortis Hospital Mulund, located in Mulund West, Mumbai, is a premier healthcare facility providing excellence in multi-speciality healthcare for over 20 years. The global leader in advancing medical technology and clinical expertise, the hospital offers specialities including Cardiology, Neurosciences, Oncology, Transplants, and Orthopaedics. The hospital is well-known for being the largest transplant center in Maharashtra and offers advanced treatment options, including Transcatheter Aortic Valve Implantation (TAVI) and stereotactic precision radiotherapy for cancer. Fortis Mulund is equipped with a 24/7 Emergency Department and International Patient Unit to provide world-class patient-centric care.

CAR-T in Fortis Hiranandani Hospital: Costs, Top Doctors, and Reviews

Mumbai, India

  • National Accreditation Board for Hospitals & Healthcare Providers (NABH)
  • Fortis Hiranandani Hospital, Vashi, Navi Mumbai, is a leading NABH-accredited multi-super speciality hospital offering advanced tertiary care with over 150 beds.
  • The hospital is known for clinical excellence in Cardiac Sciences, Oncology, Neurology, Orthopaedics, Organ Transplants, Urology, Gastroenterology, and Critical Care.
  • With a strong team of experienced doctors, modern medical technology, and international patient services, the hospital provides comprehensive and patient-focused treatment.
  • It maintains high standards of safety, hygiene, and quality care, making it a trusted healthcare destination in the Mumbai Metropolitan Region.

Need Some Advice From Our Experts?

Request a Call Back Now!

Our team of healthcare experts would be happy to assist you

trusted Patientstrusted Patients+99
Trusted by 50000+ Patients
Required | alphabets and spaces
Required | A valid, working email address
Required | A valid contact

Instantly Connect with our CAR-T Specialists

Doctor 1
Doctor 2
Doctor 3
Doctor 4
Doctor 5
Doctor 6
Doctor 7
Doctor 8
Our Services to Better your Experience

Opinion & Option

We submit the most accurate opinion and options from one or more countries for your review

Consult Privately

Consult with a certified specialist privately on our telemedicine platform even before you decide to travel

Logistics

We handle flights, visas, transfers, and accommodation—so you can focus on your health.

Recovery

Our In-house rehabilitation service packages to better your recovery and treatment outcome

Other Popular Countries for CAR-T

Our network connects you with the leading medical tourism destinations globally, offering a wide range of cities, top doctors, and flexible pricing options.

United Arab Emirates
Malaysia
Turkey
United Kingdom

Author

Dr. Vishwas Kaushik

MBBS, MD

5 Years of Experience

Dr. Vishwas Kaushik is a qualified medical professional holding an MBBS from the prestigious Belgorod State University, Russia, with a strong foundation in clinical medicine and healthcare practice. His comprehensive medical training has equipped him with a profound understanding of evidence-based clinical practices, patient-centered care, and the evolving landscape of modern medicine. With a keen interest in medical research and scientific communication, he consistently translates complex clinical concepts into clear, accurate, and accessible content for diverse audiences. His work reflects a deep commitment to advancing medical knowledge, delivering impactful healthcare insights, and bridging the gap between clinical expertise and accessible medical communication.. View More

Reviewer

Dr Prateek Varshney

Surgical Oncologist

15 Years of Experience

Dr. Prateek Varshney is a renowned Surgical Oncologist. He has experience of more than 15+ years in surgical Oncology. He is currently practicing as a consultant at Metro Mass Hospital and Cancer Institute. He was also previously associated as a consultant with Sir Ganga Ram Hospital and as a professor at Gujarat Cancer Research Institute. View More